VedTechBio RxAgentAI slashes discovery time by 50%, blending agentic GenAI with human insight for faster, more precise drug development.
VedTechBio has unveiled its upgraded RxAgentAI platform, designed to speed up drug discovery using generative, multi-agent AI. Unlike passive AI tools, RxAgentAI functions autonomously to manage complex tasks like target identification, drug design, and disease modeling. Its expert-in-the-loop system combines human oversight with AI, enhancing scientific rigor and reliability.
The platform delivers significant efficiency gains. It reduces drug identification timelines by 30% and compresses the full discovery workflow by 50%. Mapping rare disease landscapes now takes under three weeks instead of 12. These improvements reflect RxAgentAI’s ability to handle complex biomedical datasets while providing transparent, traceable outputs that aid scientific decision-making.
VedTechBio has also announced a partnership with U.S.-based AlphaMeld Corporation. The alliance combines RxAgentAI’s discovery capabilities with AlphaMeld’s real-world development pipeline. The collaboration spans from preclinical stages to human proof-of-concept, aiming to accelerate therapies for metabolic and rare diseases.
With pharma firms under pressure to reduce costs and time-to-market, RxAgentAI is drawing serious interest from U.S. and EU companies. VedTechBio’s AI-first model offers a strategic advantage: scalable drug discovery with lower overhead. The company is currently in active talks for multiple co-development deals.
